Literature DB >> 10794523

LIM domain-containing protein trip6 can act as a coactivator for the v-Rel transcription factor.

M K Zhao1, Y Wang, K Murphy, J Yi, M C Beckerle, T D Gilmore.   

Abstract

The retroviral oncoprotein v-Rel is a transcriptional activator in the Rel/NF-kappaB family of eukaryotic transcription factors. v-Rel malignantly transforms a variety of cell types in vitro and in vivo, and its transforming activity is dependent on the ability of v-Rel to bind to DNA and activate transcription. In this report, we used the yeast two-hybrid assay to identify proteins that interact with C-terminal sequences of v-Rel that are needed for transcriptional activation and transformation. One protein, Trip6, that we identified in this screen was previously identified as a thyroid hormone receptor-interacting protein. Trip6 is a member of a subfamily of LIM domain-containing proteins that are thought to transport intracellular signals from the cell surface to the nucleus. By several criteria, we show that sequences from Trip6, which include the LIM domains, behave as a coactivator for transcriptional activation by v-Rel. That is, a GAL4-Trip6 fusion protein can activate transcription in yeast and chicken cells, Trip6 can enable C-terminal sequences of v-Rel to activate transcription in yeast, and Trip6 can enhance activation by v-Rel from a kappaB site reporter plasmid in yeast. Although full-length Trip6 localizes to adhesion plaques, deletion of N-terminal sequences allows human Trip6 to enter the nucleus of chicken cells. Lastly, Northern blotting shows that Trip6 mRNA is expressed in many human tissues. Coexpression of Trip6 does not affect the transforming activity of v-Rel. Taken together, our results indicate that Trip6 may be a protein that is important for the ability of v-Rel to activate transcription and transform cells, and may represent a potential target for blocking Rel-mediated oncogenesis and transcriptional activation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10794523      PMCID: PMC6157364     

Source DB:  PubMed          Journal:  Gene Expr        ISSN: 1052-2166


  33 in total

1.  Oncogenic transformation by vrel requires an amino-terminal activation domain.

Authors:  J Kamens; P Richardson; G Mosialos; R Brent; T Gilmore
Journal:  Mol Cell Biol       Date:  1990-06       Impact factor: 4.272

2.  vRel is an inactive member of the Rel family of transcriptional activating proteins.

Authors:  P M Richardson; T D Gilmore
Journal:  J Virol       Date:  1991-06       Impact factor: 5.103

3.  Interaction of the v-Rel oncoprotein with NF-kappaB and IkappaB proteins: heterodimers of a transformation-defective v-Rel mutant and NF-2 are functional in vitro and in vivo.

Authors:  D W White; G A Pitoc; T D Gilmore
Journal:  Mol Cell Biol       Date:  1996-03       Impact factor: 4.272

4.  Different localization of the product of the v-rel oncogene in chicken fibroblasts and spleen cells correlates with transformation by REV-T.

Authors:  T D Gilmore; H M Temin
Journal:  Cell       Date:  1986-03-14       Impact factor: 41.582

5.  Using the yeast two-hybrid system to identify human epithelial cell proteins that bind gonococcal Opa proteins: intracellular gonococci bind pyruvate kinase via their Opa proteins and require host pyruvate for growth.

Authors:  J M Williams; G C Chen; L Zhu; R F Rest
Journal:  Mol Microbiol       Date:  1998-01       Impact factor: 3.501

6.  The human TRIP6 gene encodes a LIM domain protein and maps to chromosome 7q22, a region associated with tumorigenesis.

Authors:  J Yi; M C Beckerle
Journal:  Genomics       Date:  1998-04-15       Impact factor: 5.736

7.  Characterization of mouse Trip6: a putative intracellular signaling protein.

Authors:  Y Wang; J E Dooher; M Koedood Zhao; T D Gilmore
Journal:  Gene       Date:  1999-07-08       Impact factor: 3.688

8.  The retinoblastoma protein associates with the protein phosphatase type 1 catalytic subunit.

Authors:  T Durfee; K Becherer; P L Chen; S H Yeh; Y Yang; A E Kilburn; W H Lee; S J Elledge
Journal:  Genes Dev       Date:  1993-04       Impact factor: 11.361

9.  The Bcl-3 oncoprotein acts as a bridging factor between NF-kappaB/Rel and nuclear co-regulators.

Authors:  R Dechend; F Hirano; K Lehmann; V Heissmeyer; S Ansieau; F G Wulczyn; C Scheidereit; A Leutz
Journal:  Oncogene       Date:  1999-06-03       Impact factor: 9.867

10.  Ultraspiracle, a Drosophila retinoic X receptor alpha homologue, can mobilize the human thyroid hormone receptor to transactivate a human promoter.

Authors:  E Hatzivassiliou; P Cardot; V I Zannis; S A Mitsialis
Journal:  Biochemistry       Date:  1997-07-29       Impact factor: 3.162

View more
  14 in total

1.  [Down-regulation of TRIP6 expression induces actin cytoskeleton rearrangements in human carcinoma cell lines].

Authors:  O A Gur'ianova; A A Sablina; P M Chumakov; E I Frolova
Journal:  Mol Biol (Mosk)       Date:  2005 Sep-Oct

2.  A nuclear isoform of the focal adhesion LIM-domain protein Trip6 integrates activating and repressing signals at AP-1- and NF-kappaB-regulated promoters.

Authors:  Olivier Kassel; Sandra Schneider; Christine Heilbock; Margarethe Litfin; Martin Göttlicher; Peter Herrlich
Journal:  Genes Dev       Date:  2004-10-15       Impact factor: 11.361

3.  The LIM domain protein LPP is a coactivator for the ETS domain transcription factor PEA3.

Authors:  Baoqiang Guo; Rosemary E Sallis; Amanda Greenall; Marleen M R Petit; Erik Jansen; Leonie Young; Wim J M Van de Ven; Andrew D Sharrocks
Journal:  Mol Cell Biol       Date:  2006-06       Impact factor: 4.272

4.  The adaptor protein TRIP6 antagonizes Fas-induced apoptosis but promotes its effect on cell migration.

Authors:  Yun-Ju Lai; Victor T G Lin; Ying Zheng; Etty N Benveniste; Fang-Tsyr Lin
Journal:  Mol Cell Biol       Date:  2010-09-27       Impact factor: 4.272

5.  TRIP6 inhibits Hippo signaling in response to tension at adherens junctions.

Authors:  Shubham Dutta; Sebastian Mana-Capelli; Murugan Paramasivam; Ishani Dasgupta; Heather Cirka; Kris Billiar; Dannel McCollum
Journal:  EMBO Rep       Date:  2017-12-08       Impact factor: 8.807

6.  Silencing of LIMD1 promotes proliferation and reverses cell adhesion-mediated drug resistance in non-Hodgkin's lymphoma.

Authors:  Jie Tang; Liqun Zhu; Yuejiao Huang; Bing Shi; Shuqing Zhang; Lingli Gu; Jie Zhao; Minghao Deng; Jiahao Zhu; He Xun; Yuchan Wang; Chun Wang
Journal:  Oncol Lett       Date:  2019-01-11       Impact factor: 2.967

7.  c-Src-mediated phosphorylation of thyroid hormone receptor-interacting protein 6 (TRIP6) promotes osteoclast sealing zone formation.

Authors:  Brooke K McMichael; Stephanie M Meyer; Beth S Lee
Journal:  J Biol Chem       Date:  2010-06-14       Impact factor: 5.157

Review 8.  Nuclear receptors in inflammation control: repression by GR and beyond.

Authors:  Yurii Chinenov; Rebecca Gupte; Inez Rogatsky
Journal:  Mol Cell Endocrinol       Date:  2013-04-26       Impact factor: 4.102

Review 9.  TRIP6: an adaptor protein that regulates cell motility, antiapoptotic signaling and transcriptional activity.

Authors:  Victor T G Lin; Fang-Tsyr Lin
Journal:  Cell Signal       Date:  2011-06-13       Impact factor: 4.315

10.  Ajuba LIM proteins are snail/slug corepressors required for neural crest development in Xenopus.

Authors:  Ellen M Langer; Yunfeng Feng; Hou Zhaoyuan; Frank J Rauscher; Kristen L Kroll; Gregory D Longmore
Journal:  Dev Cell       Date:  2008-03       Impact factor: 12.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.